Manufacturing Partnerships Clarity has secured large-scale copper-64 manufacturing agreements with Theragenics and Nucleus RadioPharma, signaling a sales opportunity to offer end-to-end radiopharmaceutical manufacturing, supply chain, and logistics support to biopharma partners and hospital networks pursuing copper-based theranostics.

Imaging Agent Opportunity The Cu-64 SAR-bisPSMA imaging agent is moving toward potential commercial launch, with existing large-scale supply arrangements and PSMA-PET activity creating a market ready for imaging services and companion therapy collaborations across oncology centers and imaging networks.

Theranostic Leadership As a global leader in Targeted Copper Theranostics, Clarity can position its platform as a reliable, scalable, and cost-effective option for oncology programs seeking precise diagnostics and integrated diagnosis-therapy workflows with stable supply.

Funding Backing Growth Recent funding rounds underscore strong investor confidence to propel platform expansion, opening doors for co-development deals, strategic partnerships, and accelerated market access with larger pharma, clinics, and academic centers.

Trials and Adoption A diverse trial pipeline across prostate, breast, NETs, and neuroblastoma, plus investigator-initiated trials and congress engagement, creates opportunities to partner with hospitals and research centers to run studies, build evidence, and accelerate adoption of copper-based radiopharmaceuticals.